FP-CIT and MIBG scintigraphy in early Parkinson's disease

Movement Disorders

Volumn 20, Issue 5, 2005, Pages 552-561

  Spiegel, Jörg ^a   Möllers, Marc Oliver ^b   Jost, Wolfgang H ^c   Fuss, Gerhard ^a   Samnick, Samuel ^b   Dillmann, Ulrich ^a   Becker, Georg ^a   Kirsh, Carl Martin ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

Author keywords

Dopamine transporters; Noradrenaline transporters; Parkinson's disease

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; AGE; AGED; ARTICLE; BINDING KINETICS; CELL LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE DURATION; EARLY DIAGNOSIS; FEMALE; HEART SCINTISCANNING; HUMAN; MALE; MOTOR PERFORMANCE; NIGRONEOSTRIATAL SYSTEM; NUCLEAR MEDICINE; PARKINSON DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RATING SCALE; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPATHETIC NERVE CELL; SYMPTOM;

3-IODOBENZYLGUANIDINE; ADULT; AGE FACTORS; AGED; BRAIN; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PARKINSON DISEASE; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 20844463071     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20369     Document Type: Article

References (38)

1. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 1973;20:415-455.
2. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Stoof JC, Wolters EC. [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early-stage Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:294-298.
3. Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brücke T. [123I]β-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 1998;105:1213-1228.
4. Benamer HTS, Patterson J, Grosset DG. Accurate differentiation of parkinsonian and essential tremor using visual assessment of [123I]-FP-CIT-SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000;15:503-510.
5. Booij J, Bergmans P, Winogrodzka A, Speelman JD, Wolters EC. Imaging of dopamine transporters with [123I]FP-CIT does not suggest a significant effect on age on the symptomatic threshold of disease in Parkinson's disease. Synapse 2001;39:101-108.
6. Pirker W, Asenbaum S, Bencsits G, et al. [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 2000;15:1158-1167.
7. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
8. Kim YJ, Ichise M, Ballinger JR, et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA and PSP. Mov Disord 2002;17:303-312.
9. Benamer HTS, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson's disease severity and duration with [123I]-FP-CIT-SPECT striatal uptake. Mov Disord 2000;15:692-698.
10. Ichise M, Kim YJ, Ballinger JR, et al. SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa untreated Parkinson's disease. Neurology 1999;52:1206-1214.
11. Staffen W, Mair A, Unterrainer J, Trinka E, Ladurner G. Measuring the progression of idiopathic Parkinson's disease with [123I]β-CIT SPECT. J Neural Transm 2000;107:543-552.
12. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Janssen AGM, Wolters EC. [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. J Neural Transm 2001;108:1011-1019.
13. Wieland DM, Wu JI, Brown LE, et al. Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with [123I]-iodobenzylguanidine. J Nucl Med 1980;21:349-353.
14. Braune S, Reinhardt M, Bathmann J, Krause T, Lehmann M, Lücking CH. Impaired cardiac uptake of meta-[123I]iodobenzylguanidine in Parkinson's disease with autonomic failure. Acta Neurol Scand 1998;97:307-314.
15. Iwasa K, Nagajima K, Yoshikawa H, Tada A, Taki J Takamori M. Decreased myocardial 123I-MIBG uptake in Parkinson's disease. Acta Neurol Scand 1998;97:303-306.
16. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998;155:60-67.
17. Yoshita M, Hayashi M, Hirai S. Decreased myocardial accumulation of I123-meta-iodobenzylguanidine in Parkinson's disease. Nucl Med Commun 1998;19:137-142.
18. Braune S, Reinhardt M, Schnitzer R, Riedel A, Lücking CH. Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology 1999;53:1020-1025.
19. Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H.123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:189-194.
20. Satoh A, Serita T, Seto M, et al. Loss of 123I-MIBG uptake by the heart in Parkinson's disease: Assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med 1999;40:371-375.
21. Druschky A, Hilz MJ, Platsch G, et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci 2000;175:3-12.
22. Takatsu H, Nishida H, Matsuo H, et al. Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. J Nucl Med 2000;41:71-77.
23. Taki J, Nakajima K, Hwang EH, et al. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 2000;27:566-573.
24. Braune S. The role of cardiac metaiodobenzylguanidine in the differential diagnosis of parkinsonian syndromes. Clin Auton Res 2001;11:351-355.
25. Hamada K, Hirayama M, Watanabe H, et al. Onset age and severity of motor impairment are associated with reduction of myocardial (123I)-MIBG uptake in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:423-426.
26. Hughes A, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
27. Fahn S, Elton RL and members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Healthcare Information; 1987. p 153-164.
28. Laruelle M, Baldwin RM, Malison RT, et al. SPECT imaging of dopamine and serotonin transporters with [123I]β-CIT: pharmacological characterization of brain uptake in non-human primates. Synapse 1993;13:295-309.
29. Nurmi E, Bergman J, Eskola O, et al. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study. J Cereb Blood Flow Metab 2000;20:1604-1609.
30. Innis RB, Marek KL, Sheff K, et al. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]β-CIT. Mov Disord 1999;14:436-442.
31. Ahlskog JE, Uitti RJ, O'Connor MK, et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord 1999;14:940-946.
32. Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 2001;56:1559-1564.
33. The Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson's disease progression. JAMA 2002;287:1653-1661.
34. Van Lare KJ, Warwick J, Versijpt J, et al. Analysis of clinical brain SPECT data based on anatomic standardization and reference to normal data: an ROC-based comparison of visual, semiquantitative and voxel-based methods. J Nucl Med 2002;43:458-469.
35. Shinotoh H, Uchida Y, Ito H, Harrori T. Relationship between striatal [123I]beta-CIT binding and four major clinical signs in Parkinson's disease. Ann Nucl Med 2000;14:199-203.
36. Staffen W, Mair A, Unterrainer J, Trinka E, Bsteh C, Ladurner G. [123I] beta-CIT binding and SPET compared with clinical diagnosis in parkinsonism. Nucl Med Common 2000;21:417-424.
37. Gu HH, Wu X, Giros B. The NH(2)-terminus of norepinephrine transporter contains a basolateral localization signal for epithelial cells. Mol Biol Cell 2001;12:3797-3801.
38. Sjoholm H, Sundsfjord J, Mellgren SI. Beta-CIT-SPECT combined with UPDRS appears to distinguish different parkinsonian conditions. Acta Neurol Scand 2002;105:5-7.